Boosting a Natural Brain Cannabinoid Blocked Opioid Reward Without Reducing Pain Relief | Research

The takeaway

Elevating the endocannabinoid 2-AG in mice substantially reduced the rewarding effects of opioids while preserving their pain-relieving properties.

Pain researchers, addiction scientists, and pharmacologists developing strategies to combat the opioid crisis.

2-AG elevation blocked opioid reward via VTA CB1 receptors while fully preserving analgesia

What the researchers found

Pharmacologically boosting 2-AG levels via MAGL inhibition attenuated opioid reward in both conditioned place preference and self-administration paradigms without affecting opioid analgesia. The effect was mediated by CB1 receptors in the VTA. Enhancing anandamide had no effect.

Why it matters

The opioid crisis demands alternatives that provide pain relief without addiction potential. Targeting 2-AG could allow opioids to work for pain while stripping away their rewarding properties.

The numbers in context

MAGL inhibition with JZL184 attenuated opioid reward in both CPP and self-administration. VTA CB1R knockout reversed effects. FAAH inhibition (anandamide) had no effect.

How the study worked

Animal study using male and female mice. Opioid reward assessed by CPP and self-administration. CB1 receptor involvement confirmed with VTA-specific conditional knockout. Fiber photometry measured nucleus accumbens activity and dopamine transmission.

What this study cannot tell us

Mouse model may not predict human pharmacology. Long-term effects of chronic MAGL inhibition not addressed. Controlled lab settings may not reflect complex clinical scenarios.

How to read the evidence

Well-designed animal study with multiple paradigms and mechanistic confirmation, but no human data.

When this study was published

Published as a 2024 preprint on bioRxiv.

The bigger picture

If these findings translate to humans, 2-AG-boosting drugs could be co-prescribed with opioids for pain management, potentially reducing addiction risk while maintaining therapeutic benefit.

Questions still open

Would MAGL inhibitors reduce opioid misuse in humans?
Why does 2-AG but not anandamide modulate opioid reward?

Common questions

Can you make opioids less addictive?

In mice, boosting 2-AG reduced opioid reward without reducing pain relief, suggesting a possible strategy.

Does the endocannabinoid system affect opioid addiction?

2-AG acts through CB1 receptors in the brain's reward center to dampen opioid reward and reduce dopamine signaling.

Read the original research

Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.

bioRxiv : the preprint server for biology

View on PubMed ↗Publisher’s paper ↗

Citation

Martínez-Rivera, Arlene; Fetcho, Robert N; Birmingham, Lizzie; Jiu, Jin X; Yang, Ruirong; Foord, Careen; Scala-Chávez, Diego; Mekawy, Narmin; Pleil, Kristen; Pickel, Virginia M; Liston, Conor; Castorena, Carlos M; Levitz, Joshua; Pan, Ying-Xian; Briand, Lisa A; Rajadhyaksha, Anjali M; Lee, Francis S. (2024). Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2024.04.02.585967